CELL INTELLIGENCE · 肿瘤细胞治疗研究

面向实体瘤的工程化 CAR-T 细胞：通过整合设计与临床转化克服微环境

Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation.

ROBO1 CAR-NK92 细胞中 Cbl-b 敲除增强其抗肿瘤疗效

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.

淋巴毒素 β 受体在实体瘤免疫及治疗靶向中的多效性与多细胞作用

Pleiotropic and multicellular roles of lymphotoxin beta receptor in solid tumor immunity and therapeutic targeting.

重组 AAV 基因转移：在免疫调节和癌症治疗中的新兴应用

Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy.

从实验台到临床：实体恶性肿瘤 CAR-T 细胞治疗的新兴范式

From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies.

前列腺癌细胞诱导间充质干细胞中 PMEPA1 上调的体外分析

In Vitro Analysis of PMEPA1 Upregulation in Mesenchymal Stem Cells Induced by Prostate Cancer Cells.

靶向 LLT1 作为多种实体瘤中对现有检查点疗法无应答的癌症患者的潜在免疫治疗选择

Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors.

生物标志物分析显示，在来自 TCGA 和临床数据库的患者队列中，LLT1 表达升高与免疫抑制性 TME 存在明确关联。因此，本研究为将 LLT1 作为潜在靶点以改善 LLT1 上调的 ICI 无应答患者的临床反应提供了基础。

PVALB 被鉴定为与免疫密切相关的肝细胞癌独立预后因子，其缺失通过调控 NK 细胞浸润加速肿瘤进展

PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulat

简言之，PVALB 是一种预后指标，其低表达通过影响 NK 细胞浸润促进 HCC 进展。

决定肿瘤细胞命运的吞噬调节因子 CD47 的肿瘤研究进展（综述）

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review).

儿童高级别胶质瘤的 CAR-T 治疗：特殊性、当前研究与未来策略

CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.